VX-702

Item no.	HY-10401-10mg
Manufacturer	MedChem Express
CASRN	745833-23-2
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 25 mg 50 mg 5 mg
Category	Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.54
Citations	[1]Kuliopulos A, et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004, 92(6), 1387-1393.\|[2]Braddock M, IDDB Meeting Report, 2005, March 14-15.\|[3]Gill A, IDDB Meeing Report, 2002, March 06-08.\|[4]Naka K, et al. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun. 2015 Aug 20;6:8039.
Smiles	O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	745833-23-2
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Autophagy; p38 MAPK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	404.32
Product Description	VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β[1].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO: ≥ 42 mg/mL
Manufacturer - Pathway	Autophagy; MAPK/ERK Pathway
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10401-10mg-safety-datasheet.pdf